If FCR could be the procedure of preference, warning need to be taken in patients with NOTCH1 mutations, in whom rituximab seems to have minimal added value.59 Other genomic subgroups, such as sufferers with BIRC3 mutations appear to derive very little reap the benefits of CIT,111,112 but these results needs https://allang319irz8.blog2news.com/profile